We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+39.69%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.16B
AUM Growth
+$655M
Cap. Flow
-$8.33M
Cap. Flow %
-0.26%
Top 10 Hldgs %
29.57%
Holding
149
New
12
Increased
35
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$68M
2
HUM icon
Humana
HUM
+$58.7M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$21.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$21M
5
APRE icon
Aprea Therapeutics
APRE
+$19.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$49M
2
ABBV icon
AbbVie
ABBV
+$39.8M
3
SYK icon
Stryker
SYK
+$38.7M
4
MDCO
Medicines Co
MDCO
+$32.8M
5
CI icon
Cigna
CI
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 90.33%
2 Consumer Staples 0.66%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ODT
76
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$14M 0.44%
430,000
– –
KRTX
77
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$13.6M 0.43%
180,000
-180,400
-50% -$7.9M
KYNB
78
Kyntra Bio
KYNB
$29.4M
$13.1M 0.41%
12,240
– –
ZGNX
79
DELISTED
Zogenix, Inc.
ZGNX
$13M 0.41%
250,000
– –
RIGL icon
80
Rigel Pharmaceuticals
RIGL
$750M
$11.8M 0.37%
549,790
+129,790
+31% +$2.67M
MYOK
81
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11.7M 0.37%
+160,000
New +$9.7M
CNST
82
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$11M 0.35%
+233,500
New +$6.74M
BHVN
83
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.9M 0.34%
200,000
-143,500
-42% -$7.11M
ARVN icon
84
Arvinas
ARVN
$572M
$10.3M 0.32%
250,000
+100,000
+67% +$2.93M
DERM
85
DELISTED
Dermira, Inc.
DERM
$9.85M 0.31%
650,000
-125,000
-16% -$1.08M
FOLD
86
DELISTED
Amicus Therapeutics
FOLD
$9.74M 0.31%
1,000,000
– –
BMY icon
87
Bristol-Myers Squibb
BMY
$132B
$9.63M 0.3%
+150,000
New +$8.59M
DVAX
88
DELISTED
Dynavax Technologies
DVAX
$9.01M 0.28%
1,575,000
-275,000
-15% -$1.47M
QTTB icon
89
Q32 Bio
QTTB
$464M
$8.8M 0.28%
23,611
– –
TVTX icon
90
Travere Therapeutics
TVTX
$5.78B
$8.16M 0.26%
575,000
-375,000
-39% -$4.79M
RYTM icon
91
Rhythm Pharmaceuticals
RYTM
$7.96B
$7.92M 0.25%
345,000
+40,000
+13% +$889K
MNTA
92
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$7.89M 0.25%
400,000
– –
MYOV
93
DELISTED
Myovant Sciences Ltd.
MYOV
$7.76M 0.25%
500,000
+50,000
+11% +$504K
TBIO
94
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$7.73M 0.24%
950,000
-75,000
-7% -$692K
MRSN
95
DELISTED
Mersana Therapeutics
MRSN
$7.07M 0.22%
49,320
-6,680
-12% -$488K
PHAS
96
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$6.87M 0.22%
1,125,000
-291,900
-21% -$1.2M
ICPT
97
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$6.74M 0.21%
54,400
– –
GRTX
98
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$6.58M 0.21%
+500,000
New +$6.1M
CGEN icon
99
Compugen
CGEN
$228M
$6.56M 0.21%
1,100,000
– –
NGM
100
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$6.49M 0.21%
351,100
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rock Springs Capital Management held 149 positions worth $3.16B, up 26% from $2.51B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2019 filing shows 12 new, 35 increased, 32 reduced and 19 closed positions. Its largest new stake was Humana: 185,000 shares worth $67.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2019 buy was Humana: 185,000 shares worth $67.8M.
  • Rock Springs Capital Management added most to Johnson & Johnson in Q4 2019, an estimated $68M increase.
  • Rock Springs Capital Management's biggest Q4 2019 reduction was Medicines Co, cutting an estimated $32.8M.
  • Rock Springs Capital Management fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $3.16B portfolio in Q4 2019.
  • Rock Springs Capital Management opened 12 new positions and closed 19 in Q4 2019.
  • Rock Springs Capital Management's portfolio value rose 26% quarter-over-quarter to $3.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.